根据许可协议，康宁杰瑞有权收取最高合共人民币30.8亿元的预付款及里程碑付款，其中包括收取人民币4亿元的预付款，与多项注册临床试验的首例患者入组相关的开发里程碑付款人民币3亿元，根据监管审批进展收取的监管里程碑付款和销售里程碑付款。此外，康宁杰瑞亦有权收取JSKN003的产品销售净额两位数百分比的特许权使用费。Kangning Jerui Pharmaceuticals-B (09966) soared by more than 40%, as of the deadline, rose 34.31%, trading at HK$4.11, with a turnover of 141.032 million Hong Kong dollars.
According to the Zhixun Finance APP, Kangning Jerui Pharmaceuticals-B (09966) soared by more than 40%, as of the deadline, rose 34.31%, trading at HK$4.11, with a turnover of 141.032 million Hong Kong dollars.
On the news front, Kangning Jerui announced that it has signed a licensing agreement with Jingman Te Bio-technology, a wholly-owned subsidiary of CSPC Pharma, to develop, sell, commit to sell, and commercialize JSKN003 (a dual-site targeted HER2 antibody-drug conjugate) in mainland China for the treatment of tumor-related indications. Under the terms of the license agreement, Jingman Te Bio-technology will receive exclusive licensing and sublicense rights to develop, sell, commit to sell, and commercialize JSKN003. Kangning Jerui will retain exclusive rights to supply JSKN003 for any purpose within and outside that region.
According to the license agreement, Kangning Jerui has the right to receive a total of up to RMB 3.08 billion in upfront and milestone payments, including receiving an upfront payment of RMB 0.4 billion, development milestone payments of RMB 0.3 billion related to the first patient enrolled in multiple registered clinical trials, regulatory milestone payments based on regulatory approval progress, and sales milestone payments. In addition, Kangning Jerui also has the right to receive a double-digit percentage of the net sales of JSKN003 as royalties.